Aberrant RNA Processing in a Neurodegenerative Disease: the Cause for Absent EAAT2, a Glutamate Transporter, in Amyotrophic Lateral Sclerosis  by Lin, Chien-Liang Glenn et al.
Neuron, Vol. 20, 589±602, March, 1998, Copyright 1998 by Cell Press
Aberrant RNA Processing in a Neurodegenerative
Disease: the Cause for Absent EAAT2, a Glutamate
Transporter, in Amyotrophic Lateral Sclerosis
(Brown, 1996; Siddique and Deng, 1996). Consequently,
multiple mechanisms have been postulated to be the
cause of this form of the disease, including excitotoxicity
(Shaw, 1994; Rothstein, 1996), oxidative injury (Bowling
et al., 1995; Borthwick et al., 1996), cytoskeletal abnor-
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Baltimore, Maryland 21287 malities (Lee et al., 1994; Wong et al., 1995; Bruijn and
Cleveland, 1996), and autoimmunity (Smith et al., 1992;
Appel et al., 1994). Glutamate-mediated excitotoxicity
has been suspected to contribute to motor neuron de-Summary
generation in ALS because of: (1) loss of high affinity
glutamate transport (Rothstein et al., 1992; Shaw et al.,Amyotrophic lateral sclerosis (ALS) is a neurodegener-
1994), (2) other abnormalities in glutamate metabolismative disease that is characterized by selective upper
(Rothstein et al., 1990; Couratier et al., 1993, 1994; Shawand lower motor neuron degeneration, thepathogene-
et al., 1995), (3) susceptibility of motor neurons to gluta-sis of which is unknown. About 60%±70% of sporadic
mate toxicity (Ince et al., 1993; Rothstein et al., 1993;ALS patients have a 30%±95% loss of the astroglial
Carriedo et al., 1995; Ikonomidou et al., 1996), and (4)glutamate transporter EAAT2 (excitatory amino acid
clinical efficacy of anti-glutamate agents (Bensimon ettransporter 2) protein in motor cortex and spinal cord.
al., 1994; Lacomblez et al., 1996; Miller et al., 1996).Loss of EAAT2 leads to increased extracellular gluta-
High affinity sodium-dependent glutamate transportmate and excitotoxic neuronal degeneration. Multiple
is the primary means of inactivating neurotransmitterabnormal EAAT2 mRNAs, including intron-retention
glutamate. EAAT1 and EAAT2 are glutamate transport-and exon-skipping, have now been identified from the
ers specific for astrocytes (Rothstein et al., 1994, 1995;affected areas of ALS patients. The aberrant mRNAs
Lehre et al., 1995), while neuronal glutamate transportwere highly abundant and were found only in neuro-
is mediated by EAAT3 and EAAT4 (Arriza et al., 1994;pathologically affected areas of ALS patients but not
Rothstein et al., 1994; Fairman et al., 1995; Furuta et al.,in other brain regions. They were found in 65% of
1997). Antisense knockdown and other studies suggestsporadic ALS patients but were not found in nonneuro-
that EAAT2 is the predominant glutamate transporterlogic disease or other disease controls. They were
(Haugeto et al., 1996; Rothstein et al., 1996). Detailedalso detectable in the cerebrospinal fluid (CSF) of living
studies of ALS and other neurodegenerative diseasesALS patients, early in the disease. In vitro expression
have shown that impaired glutamate transport in ALSstudies suggest that proteins translated from these
appears to be due to a loss of only the EAAT2 protein. Upaberrant mRNAs may undergo rapid degradation and/
to 60%±70% of sporadic ALS patients have a 30%±95%or produce a dominant negative effect on normal EAAT2
loss of EAAT2 protein (Rothstein et al., 1992, 1995; Shawresulting in loss of protein and activity. These findings
et al., 1994).suggest that the loss of EAAT2 in ALS is due to aber-
What could account for the selective loss of EAAT2rant mRNA and that these aberrant mRNAs could re-
protein in ALS? It does not appear to be due to de-sult from RNA processing errors. Aberrant RNA pro-
creased overall transcription of the EAAT2 mRNA in ALScessing could be important in the pathophysiology of
(Bristol and Rothstein, 1996), nor is there evidence forneurodegenerative disease and in excitotoxicity. The
genomic mutations of EAAT2 in familial or sporadic ALSpresence of these mRNA species in ALS CSF may have
(Aoki et al., 1998). We now report that aberrant EAAT2diagnostic utility.
mRNA species appear to account for the regional selec-
tive loss of EAAT2 and occur commonly in the sporadicIntroduction
form of ALS.
Amyotrophic lateral sclerosis (ALS) is an adult-onset
chronic neuromuscular disorder that is clinically charac- Results
terized by muscle wasting, weakness, and spasticity,
reflecting the relatively selective degeneration of cortical Identification of Aberrant EAAT2 Transcripts
motor neurons and spinal/bulbar motor neurons (Kuncl in ALS Affected Areas
et al., 1992). ALS is uniformly fatal due to respiratory A male ALS patient (66 years old, 5 hr postmortem delay)
impairment. The disease is present worldwide; 95% of without SOD1 mutations was initially investigated. This
all cases are sporadic, with many of the remaining 5% patient was chosen because immunoblot studies re-
of cases showing an autosomal dominant inheritance vealed extremely low levels of EAAT2 protein (5% of
(Brown, 1996; Siddique and Deng, 1996). About 15%± control) in motor cortex (Rothstein et al., 1995). The
25% of familial ALS, reflecting 1% of all ALS patients, Northern blotting revealed that the quantity and size of
is due to mutations of Cu21/Zn1 superoxide dismutase EAAT2 mRNA were normal (Bristol and Rothstein, 1996).
(Brown, 1996; Siddique and Deng, 1996). These muta- To investigate whether there were aberrant EAAT2
tions are not present in the sporadic ALS population mRNA species, a cDNA library was constructed from a
poly(A)1 mRNA prepared from the motor cortex of this
patient. The cDNA library was then screened, and an*To whom correspondence should be addressed.
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Figure 1. Structure of Aberrant EAAT2 mRNA
in ALS
(A) Schematic presentation of abnormally
processed partial intron7±retention and exon
9±skipping species in relation to the normal
EAAT2 gene. Numbered boxes represent in-
dividual exons. The connected arrow heads
indicate the primer regions used for RT-PCR.
The hatched bars indicate the regions used
to prepare probes for in situ hybridization.
Probe E corresponds to position 1687±2210
from the 59 translation region. Probe F corre-
sponds to position 537±1008 from the exon
7 intron junction. The triangle indicates a Hind
III site used as an insertion site for con-
structing an internal control plasmid pE2F.
(B) Sequencing analysis of truncated EAAT2
transcripts present in ALS. In the right panel,
twenty nucleotides on both sides of each
internal deletion transcript are displayed.
Arrows indicate splicing junctions. Sequences
between the arrows are spliced out. Dashed
lines indicate nucleotides within the deleted
sequences. A schematic representation of
the deleted regions is presented in the right
panel. Gray boxes represent regions of miss-
ing RNA sequence.
abnormal cDNA clone was subsequently identified from which was amplified along with the normal-size PCR
fragment in the patient but was not present in normalpositive clones by restriction analysis. Sequencing of
this clone revealed that it contained 1091 bp of the controls (Figure 2A; at exon 9±skipping EAAT2; ALS pa-
tient 2). The shorter PCR fragment was cloned. DNAEAAT2 coding region from exon 1 to exon 7, followed
by 1008 bp of intron region, corresponding to partial sequencing revealed it to be a 135 bp in-frame deletion
in which exon 8 is linked directly to exon 10, demonstrat-sequence of intron 7, ending with a poly A tail (Aoki et
al., 1998; Figure 1A). A stop codon was found immedi- ing that it arises from skipping exon 9 (Aoki et al., 1998;
Figure 1A).ately after this exon and intron junction. Thus, the pre-
sumed translation product would be EAAT2protein trun- Furthermore, when primers D and C (Figure 1A) were
used to amplify the full-length EAAT2 coding region, acated after codon 364.
To ensure that this was not a cloning artifact, reverse- large amount of shorter PCR fragments was observed
in motor cortex of ALS but not in normal controls (Figuretranscription polymerase chain reaction (RT-PCR), with
the use of a primer pair that included normal exonic and 2C). All of the shorter PCR fragments from ALS patient
3 (Figure 2C) were then cloned. Twenty clones wereintronic sequences (Figure 1A, primers A and B), was
performed on equal amounts of poly(A)1 mRNA (DNase randomly selected and analyzed byrestriction digestion.
All of the these clones were found to have differentI treated) prepared from motor cortex of the ALS patient
and normal controls. As shown in Figure 2A (at intron- internal deletions. In addition, a single band from the
gel (Patient 3, Figure 2C) was cloned and was found toretention EAAT2; ALS patient 3), a strong signal was
observed in the ALS specimen but not in the control consist of multiple internally deleted cDNA, all similar in
size. These results indicate that there are many differentspecimens.
As another approach, we also used RT-PCR toamplify truncated EAAT2 transcripts in ALS motor cortex.
Eight of the truncated cDNAs were then sequencedEAAT2 cDNA fragments from poly(A)1 mRNA prepared
from the spinal cord or motor cortex of the patient and at the junction of the deletion regions (Figure 1B). Two
cDNAs were found to betruncated due toexon-skippingfrom normal controls. A shorter PCR fragment was sub-
sequently identified, using primers A and C (Figure 1A), (Figures 1B7 and 1B8). One cDNA was truncated at the
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Figure 2. Aberrant mRNA Species Are Com-
monly Present in ALS but Not Control Motor
Cortex
(A) Analysis of EAAT2 protein (Western blot)
andaberrant EAAT2 mRNA species (RT-PCR/
Southern blot) in ALS and control motor cor-
tex. Aliquots of tissue homogenates from
control or ALS motor cortex were subjected
to SDS-polyacrylamide gel electrophoresis
and immunoblotted with affinity-purified poly-
clonal carboxy-terminal antibody to EAAT2.
Controls included nonneurological and neu-
rodegenerative disease specimens. Individ-
ual lanes are numbered for each patient.
RT-PCR was performed on parallel tissue
samples from each control or ALS motor cor-
tex specimen. An internal control was de-
signed for comparative analysis of the partial
intron 7±retention mRNA between samples.
(B) Exon 9±skipping EAAT2 mRNA is present
in some ALS CSF specimens.
(C) RT-PCR for full-length EAAT2 reveals mul-
tiple truncated transcripts in ALS but not in
controls. The aberrant species were present
in motor cortex but not cerebellum (Cblm) or
hippocampus (Hipp). Lane numbers are iden-
tical to patients labeled in (A).
(D) No aberrant EAAT1 or SMN transcripts
were found in ALS motor cortex. Lane num-
bers are identical to patients labeled in (A).
appropriate splicing donor and acceptor sites (Figure Thus, several observations suggest that these aber-
rant RNA species were specific for ALS and were not1B5). Other truncated cDNAs were identified, although
the deletions did not occur at common splicing sites an artifact. Theywere not observed in otherneurodegen-
erative disorders, including Huntington's disease, Alz-(Figures 1B1±1B4 and 1B6). The presence of multiple pre-
cise exon-skipping deletions (Figures 1A and 1B) sug- heimer's disease, and spinal muscular atrophy; they
were found only in neuropathologically affected braingests that it is very unlikely that they could be caused
by somatic DNA deletions. The abundance of multiple regions, while unaffected brain regions in the same pa-
tients had normal EAAT2 RNA. Other transporter pro-truncated transcripts may be the result of aberrant RNA
splicing. teins, as well as constitutive RNA species, were not
affected.To examine the specificity of these defects for brain
region and transporter subtypes, ALS and control tissue
from several brain regions in the same patient were The Aberrant EAAT2 Transcripts
Are Present In Vivoexamined. As shown in Figure 2C, multiple truncated
EAAT2 mRNAs were found in ALS motor cortex but not To verify that these aberrant EAAT2 transcripts were
present in vivo and not a cloning or PCR artifact, incerebellum or hippocampus from the same patient (3).
Similar results were obtained from every ALS patient situ hybridization was performed to detect partial intron
7±retention mRNA using a riboprobe to the intronic re-examined (n 5 20). Other cell-specific and general cellu-
lar mRNA species were examined.Truncated transcripts gion (Figure 1A, probe F). Figures 3A and 3B show that
this partial intron 7±retention mRNA was present onlywere not found for the astroglial glutamate transporter
EAAT1 (Figure 2D), the neuronal protein EAAT3, or the in ALS motor cortex, but not in control specimens, in
agreement with the RT-PCR results. In addition, signalsconstitutive spliceosomal assembly protein (the survival
motor neuron [SMN]) (Fischer et al., 1997; Liu et al., were uniformly localized to small cells, presumably
astrocytes, present throughout the motor cortex (EAAT21997; Figure 2D). EAAT1 and EAAT3 protein levels were
previously shown to be normal in ALS (Rothstein et al., is an astrocyte-specific protein) (Figure 3D, asterisk). As
a control, signals for actin (Figures 3C and 3F) were1995).
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Figure 3. In Situ Hybridization of Partial Intron 7-Retention mRNA in Motor Cortex
The partial intron 7±retention mRNA was localized to small cells throughout the motor cortex in ALS (A) but was not detected in control motor
cortex (B). When compared to mRNA for the general cellular protein actin (C), the localization appeared to be consistent with astrocytes.
Higher power analysis ([D], [E], and [F]) of ALS motor cortex confirmed that aberrant partial intron 7±retention mRNA was localized to small
cortical cells ([D], asterisk), identical to the localization of wild-type EAAT2 mRNA in ALS cortical astrocytes (E), whereas actin was localized
in both astrocytes and neurons ([F], arrow) in ALS motor cortex. The localization of the partial intron 7±retention EAAT2 mRNA (A) correlated
with the decreased expression of EAAT2 protein (G) in ALS compared with expression of EAAT2 protein in controlmotor (H) cortex. Immunohisto-
chemistry and in situ hybridization studies were performed on three different specimens. Scale bar, 0.1 mm for (A), (B), (C), (G), and (H); 0.01
for (D), (E), and (F).
found to be expressed by both neurons (arrowhead) and provides evidence that these aberrant splicing EAAT2
transcripts were present in vivo. Northern analysis ofastroglia. Wild-type EAAT2 mRNA in ALS (Figure 3E)
and in control tissue (data not shown) was expressed EAAT2 mRNA could not be used for this purpose be-
cause the size of normal EAAT2 mRNA is about 11 kbin a distribution similar to the partial intron 7±retention
mRNA. No staining was seen with sense controls (data and the truncated transcript would only be z1±2 kb
smaller. Therefore, it would be difficult to identify thesenot shown). Furthermore, the dramatic loss of EAAT2
protein (Rothstein et al., 1995; Figures 3G and 3H) in truncated transcripts from full length transcript using
this method.ALS motor cortex appears to be associated with the
presence of the partial intron 7±retention transcripts,
which was specific to ALS and was not detected in Up to 70% of Total EAAT2 Transcripts Are
Aberrant RNA Processing Productsmotor cortex from control specimens (Figure 3B) or in
specimens of motor cortex from ALS patients that were To determine the abundance of the aberrant mRNA spe-
cies relative to wild-type EAAT2, we performed quantita-not RT-PCR±positive for the intron-retention transcripts
(data not shown). Finally, S1 nuclease protection analy- tive RT-PCR using mRNA from ALS patient 4. This pa-
tient was chosen because RT-PCR studies revealed onlysis of EAAT2 mRNA (Figure 4C; described below) also
Aberrant Glutamate Transporter mRNA in ALS
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Figure 4. Quantitative Analysis of Aberrant
EAAT2 mRNA in ALS Motor Cortex
(A) Quantitative RT-PCR analysis of EAAT2
mRNA from ALS patient 4. PCR reaction
products from different amplification cycles
were subjected to Southern blot analysis us-
ing an oligonucleotide probe located at the
39 end of the PCR fragment. Abbreviations:
wt, wild-type EAAT2; tr-1 and tr-2, two trun-
cated aberrant species.
(B) The amounts of radioactivity recovered
from the excised membrane bands in (A) were
plotted as a function of the number of cycles.
The rates of amplification were exponential
between 14 and 24 cycles for full length and
truncated templates. More than 70% of total
EAAT2 mRNA is in the form of aberrant tran-
scripts.
(C) S1 nuclease protection analysis of EAAT2
mRNA using a 836 base single strand DNA
probe, located at the 39 end of the coding
region. A schematic representation of the
probe, the wild-type mRNA, and the aber-
rantly spliced mRNA (tr-2) are shown on the
right. The protection fragments were sub-
jected to Southern blot analysis using an oli-
gonucleotide probe located at the 39 end of
the protection fragment. As with quantitative
RT-PCR, the abnormal species were abun-
dant in the ALS specimens compared to nor-
mal EAAT2.
two typesof truncated transcripts (Figure 2C). PCR reac- protection fragments, which is in agreement with the
quantitative RT-PCR results (Figure 4B).tion products from different amplification cycles were
resolved by gel electrophoresis and transferred to mem-
brane for Southern blot analysis (Figure 4A). The amount Aberrant EAAT2 Transcripts Are Commonly Present
in Sporadic ALS and They Are Correlatedof radioactivity recovered from the excised membrane
bands was plotted as a function of the number of cycles with Loss of EAAT2 Protein
To evaluate the prevalence of these aberrant EAAT2(Figure 4B). The rates of amplification were exponential
between 14 and 24 cycles for full-length and truncated transcripts in ALS, 30 ALS specimens were screened,
including spinal cord, motor cortex, and cerebellum, fortemplates. The results revealed that full-length (wild-
type) and truncated transcripts tr-1 and tr-2 represent partial intron 7±retention and exon 9±skipping tran-
scripts by competitive RT-PCR (Figure 2A). An internal28%, 2%, and 70% of total EAAT2 transcript, respec-
tively. It is notable that the truncated transcript tr-2 from control was designed to amplify along with the partial
intron 7±retention mRNA (Figure 1A; see Experimentalthis patient is the same as the transcript in Figure 1B7.
As described below, this truncated transcript produced Procedures). Since the exon 9±skipping mRNA was 135
bp shorter than the wild-type EAAT2 mRNA, the wild-downregulation of normal EAAT2 in vitro.
We also performed S1 nuclease protection assays to type EAAT2 mRNA was used as an internal control for
the comparative analysis of the exon 9±skipping mRNAevaluate the relative abundance of the aberrant mRNA
species. A 836 base single-strand DNA probe located between patients. All RT-PCR experiments were re-
peated 2±5 times for each specimen to verify the pres-at the 39 end of the coding region was used. The S1
nuclease-resistant fragments were resolved by gel elec- ence of aberrant mRNA species. Both aberrant tran-
scripts were commonly found; 20 of the 30 ALS patientstrophoresis and transferred to membrane. The blot was
probed with an oligonucleotide probe located at the 39 had the partial intron 7±retention mRNA and 11 of the
30 ALS patients had the exon 9±skipping mRNA. Theseend of the protection fragment. As shown in Figure 4C,
large amounts of ,836 bp S1 nuclease-resistant frag- aberrant mRNA species were found only in ALS motor
cortex, or spinal cord, or both, but not in cerebellum.ments were observed in ALS specimens but were not
seen in the control specimens. The mRNA sample from To determine the disease specificity of these aberrant
mRNA species, other nonneurological and neurologicalALS patient 4 used in this experiment was the same one
used for quantitative RT-PCR described above. The 346 disease control tissues were examined (Table 1), includ-
ing tissue from neuropathologically affected and unaf-bp S1 nuclease-resistant fragment, corresponding to
the truncated transcript tr-2, represents 73% of the total fected regions. The aberrant mRNA species were not
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Table 1. ALS and Control Populations Used for the Analysis of EAAT2 Mutations
Number of Age at Death Postmortem Delay (hr)
Group Patients M/F (mean year 6 SEM) (mean 6 SEM)
ALS 30 23/7 60.4 6 2.1 7.3 6 0.8
Nonneurological disease 25 15/19 65.2 6 2.2 10.4 6 0.6
SMA* 8 3/5 6.6 6 1.0 (month) 9.3 6 1.8
Alzheimer's disease 7 4/3 74.8 6 2.1 8.2 6 0.6
Huntington's disease 6 2/4 59.3 6 4.9 11.9 6 0.7
* SMA 5 spinal muscular atrophy, type 1.
found in any of the neural tissues from a total of 48 dementia. The exon 9±skipping mRNA was not detected
in the 38 control specimens but was detected in 12 outcontrols, including 27 nonneurological disease control
specimens (12 spinal cord and 27 motor cortex), 8 spinal of 18 (66%) ALS specimens. In addition, in four ALS
cases (Table 2), CSF obtained during diagnostic evalua-muscular atrophy specimens (SMA-type 1) (spinal cord),
7 Alzheimer's disease specimens (7 hippocampus and tion and brain tissue obtained at autopsy were available
from the same patients. In those patients, CSF was col-7 motor cortex), and 6 Huntington's disease specimens
(6 caudate and 6 motor cortex). The control tissues were lected 25.5 6 6 (SEM) months prior to death. In all cases,
the presence of the exon 9±skipping mRNA was de-matched for age and postmortem delay (Table 1).
The presence of abnormal mRNA was significantly tected in both antemortem CSF and postmortem brain
or spinal cord tissue.(p , 0.001) correlated with the loss of EAAT2 protein.
ALS specimens from motor cortex or spinal cord that
had very low levels of EAAT2 protein (,30% of control) Proteins Translated from These Aberrant Transcripts
Are Unstable and/or Cause Downregulationcontained both partial intron 7±retention and exon 9±skip-
ping transcripts (Figure 5A). Eight out of 30 ALS patients of Normal EAAT2 In Vitro
To determine if proteins translated from these aberranthad both partial intron 7±retention and exon 9±skipping
mRNA. An intermediate loss of EAAT2 protein in neural EAAT2 transcripts could be identified in the ALS post-
mortem tissue, we analyzed ALS motor cortex for a car-tissue, 30%±80% of control levels, was associated with
the presence of the partial intron 7±retention mRNA boxy-terminal truncated EAAT2 protein (the presumed
protein product of the partial intron 7±retention tran-alone. In addition, the loss of EAAT2 protein was in-
versely correlated with the amounts of either the exon script) by Western blotting with amino-terminal oligo-
peptide antibodies to human EAAT2 protein (Rothstein9±skipping (rs 5 0.81, p , 0.001) or the partial intron
7±retention mRNA (rs 5 0.62, p , 0.001; Figure 5B). et al., 1995). Previous studies have shown that the
amino-terminal antibody can recognize wild-type EAAT2Although the presence of aberrant mRNA species ap-
peared to correlate with a loss of protein, rarely did in human tissue. However, using this antibody, no immu-
noreactive band with the expected size of the truncatedpatients with a loss of EAAT2 not have either of these
aberrant mRNA. In those cases, the loss of protein could EAAT2 protein was detected. The protein from the exon
9±skipping transcript was also investigated in ALS tis-be due to other as yet unidentified variants in EAAT2
mRNA. Alternatively, other mechanisms known to lead sue, using oligopeptide antibodies to the amino acid
sequence spanning the deletionsite. Again, no immuno-to degradation of glutamate transporter proteins, e.g.,
oxidative stress, could have resulted in a loss of EAAT2 reactive band was detected (data not shown). The inabil-
ity to detect the aberrant EAAT2 proteins could be due(Volterra et al., 1994; Trotti et al., 1996).
The presence of the aberrant mRNA species did not to several possibilities: (1) the aberrant EAAT2 proteins
could be very unstable or rapidly degraded in postmortemcorrelate with the clinical presentation (spinal versus
bulbar onset) of the disease in ALS patients. ALS pa- tissue, or both, or (2) the aberrant proteins may not be
detectable with the available antibodies, or (3) the aber-tients with altered EAAT2 mRNA species had a tendency
toward shorter survival (17 6 2.9 [SEM] months) when rant proteins may also affect normal EAAT2 function.
To evaluate the properties of these abnormal tran-compared to the overall average for ALS of 2±5 years
(Kuncl et al., 1992) but not when compared to the ALS scripts, EAAT2 cDNA was transiently expressed in
COS7 cells. EAAT2 protein was quantitated 72 hr post-patients in this study without aberrant mRNA species
(23 6 4.8 [SEM] months). transfection by Western blotting, and activity of the
transporter was measured by a sodium-dependent 3H-
glutamate transport assay (Rothstein et al., 1992, 1995).Detection of Aberrant EAAT2 Transcripts
in Cerebrospinal Fluid Wild-type EAAT2 protein was detected by a carboxy-
terminal EAAT2 antibody (Figure 6A, lane 1) as well asCerebrospinal fluid (CSF) was also examined for the
presence of the exon 9±skipping transcript in ALS and evidence of glutamate transport. Wild-type EAAT2 was
not detected by the available amino-terminal antibody.control specimens (Figure 2B). All specimens were pro-
cessed identically. Control CSF was obtained from pa- As expected, predicted truncated protein synthesized
from the partial intron 7±retention cDNA was not de-tients with neurological diagnoses that included multiple
sclerosis, normal pressure hydrocephalus, hepatic en- tectedby thiscarboxy-terminal antibody (Figure 6A, lane
5). Nevertheless, there was evidence that the partialcephalopathy, migraine headache, subarachnoid hem-
orrhage, stroke, epilepsy, ataxia, CNS vasculitis, and intron 7±retention EAAT2 cDNA was expressed by the
Aberrant Glutamate Transporter mRNA in ALS
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Figure 5. Aberrant EAAT2 mRNA Species Correlate with the Loss of EAAT2 Protein
(A) Identification of both (closed circle) partial intron 7±retention and exon 9±skipping mRNA species in the same tissue samples was typically
associated with a large loss of EAAT2 protein, while the presence of partial intron 7±retention alone (closed triangle) or trace amounts of
partial intron 7±retention mRNA sequence (open triangle) was associated with moderate to little loss of EAAT2 protein. Absence of the
abnormally processed mRNA (open square) was associated with normal levels of EAAT2 protein.
(B) The amounts of partial intron 7±retention and exon 9±skipping mRNA species in spinal cord and motor cortex were inversely correlated
with the amount of EAAT2 protein.
COS7 cells, because the partial intron 7±retention mRNA (Figure 6A, lanes 2±4). The same results were obtained
whenthe partial intron7±retentioncDNA wascoexpressedwas detected in the transfected cells by Northern blot-
ting and RT-PCR (data not shown). No glutamate trans- in HeLa cells (Figure 6A, lanes 6±7). These coexpression
studies suggest that the partial intron 7±retention cDNAport was observed in COS7 cells transfected with the
partial intron 7±retention cDNA. could dominantly downregulate EAAT2 protein. This ef-
fect was specific for EAAT2; coexpression of the intron-When thepartial intron 7±retention cDNA was cotrans-
fected with the normal EAAT2 cDNA into COS7 cells, retention cDNA with wild-type EAAT1, EAAT3, or EAAT4
cDNA had no effect on either the astroglial subtypethere was a progressive decrease in the level of normal
EAAT2 protein (Figure 6A, lanes 2±4). However, the lev- EAAT1 (Figure 6A, lanes 8 and 9) or the neuronal sub-
types EAAT3 and EAAT4 (data not shown) protein orels of wild-type EAAT2 mRNA, using Northern analysis,
were not decreased by the partial intron 7±retention glutamate transport. This effect is not due to the pro-
moter competition between wild-type and partial introncDNA (Figure 6A, lanes 2±4). Glutamate transport also
decreased in parallel with the loss of EAAT2 protein 7±retention cDNA because (1) the levels of wild-type
Table 2. Exon 9±skipping EAAT2 Species Are Present in ALS CSF Years Prior to Death: Examination of CSF and Postmortem
Brain Specimens
Age Disease CSF Collection: Exon 9-Skipping EAAT2
Patient (at Death) Duration Time before Death (RT-PCR)
(months) (months) CSF Brain
1 44 39 27 1 1
2 52 46 41 1 1
3 62 15 12 1 1
4 63 22 22 2 2
1 Exon 9±skipping EAAT2 present in sample; 2 exon 9±skipping species not detectable.
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Figure 6. Transient Expression of the Par-
tial Intron 7-Retention and Exon 9±Skipping
EAAT2 cDNA in COS7 Cells and in HeLa Cells
Different combinations of indicated plasmids
were transfected into COS7 cells ([A], para-
digms 1±5 and 8±9; [B], paradigms 1±3) or
HeLa cells ([A], paradigms 6 and 7) by elec-
troporation. After 72 hr, some transfected
cells were used to quantitate expressed
EAAT2 or EAAT1 protein by immunoblotting
using carboxyterminal oligopeptide antibod-
ies to EAAT2 or EAAT1 protein, or EAAT2
mRNA expression by Northern blot. Others
were used to measure functional EAAT2 or
EAAT1 by sodium-dependent, 3H-glutamate
transport assay.
(A) The partial intron 7±retention EAAT2 cDNA
produced a negative effect on the normal
EAAT2 protein level and glutamate transport
(paradigms 1±7) but had no effect on EAAT2
mRNA levels (paradigms 1±5), EAAT1 protein
levels (paradigms 8 and 9), or EAAT1 gluta-
mate transport (paradigms 8 and 9).
(B) The exon 9±skipping EAAT2 species had
no effect on EAAT2 protein expression (para-
digm 3) or on wild-type glutamate transport
(paradigm 3). All aberrant or wild-type EAAT2
(EAAT1) cDNAs were in the same vector
(pcDNA3).
EAAT2 mRNA were not decreased and (2) this effect cells. Expression of fusion proteins was examined by
Western blotting using anti-GFP antibodies (Figure 7A).was not observed in other subtypes of glutamate trans-
porters with the same vector and transfection condi- Both the partial intron 7±retention (Figure 7A, lane 3)
and the exon 9±skipping (Figure 7A, lane 4) EAAT2-tions.
The exon 9±skipping EAAT2 cDNA was also ex- GFP proteins were expressed at the expected lower
molecular weights. Furthermore, the mutant EAAT2-pressed in COS7 cells. Although the protein was not
detected by Western blotting (Figure 6B, lane 2), the GFPs appeared to be unstable compared to the wild-
type EAAT2-GFP (Figure 7A, lane 2), as judged by themRNA was detected in the transfected COS7 cells by
RT-PCR. However, no glutamate transport was ob- presence of less protein and multiple lower molecular
weight species (Figure 7A, lanes 3 and 4).served in the transfected COS7 cells by sodium-depen-
dent 3H-glutamate transport assay. Notably, in this para- The cellular localization of the fusion proteins was then
examined by fluorescent microscopy. Wild-type EAAT2-digm, the exon 9±skipping cDNA had no effect on the
expression of wild-type EAAT2 protein or glutamate GFP was preferentially localized to the cell surface (Fig-
ure 7B). However, both the partial intron 7±retention andtransport (Figure 6B, lane 3).
To confirm that the aberrant EAAT2 cDNAs were ex- the exon 9±skipping EAAT2-GFP fusion proteins were
restricted to the cytoplasm, were often peri-nuclear (Fig-pressed and translated, we constructed chimeric genes
to encode C-terminal fusions of wild-type or mutant ure 7B), and were found occasionally in lysosomes (data
not shown). When wild-type EAAT2-GFP was coex-EAAT2 to green-fluorescent protein (GFP). These con-
structs were expressed in COS7 cells and all produced pressed with the partial intron 7±retention EAAT2 (not
GFP-labeled), the wild-type protein was found largelysimilar levels of mRNA by Northern blotting (data not
shown). The wild-type EAAT2-GFP±transfected cells confined to the cytoplasm, with occasional cell mem-
brane staining (Figure 7B). The same results were ob-had normal 3H-glutamate transport activity (data not
shown) when compared to non-GFP EAAT2-transfected served from coexpression of partial intron 7±retention
Aberrant Glutamate Transporter mRNA in ALS
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Figure 7. Expression of Normal and Aberrant EAAT2 Fused with Green-Fluorescent Protein (GFP) in COS7 Cells
(A) Immunoblot of COS7 cells expressing EAAT2-GFP fusion protein using anti-GFP antibody. Lane 1, pEGFP vector; lane 2, wild-type EAAT2-
GFP; Lane 3, partial intron 7±retention EAAT2-GFP; Lane 4, exon 9±skipping EAAT2-GFP; and lane 5, COS7 cells alone. The partial intron
7±retention and exon 9±skipping mRNA produced truncated, unstable proteins.
(B) Visualization of normal and aberrant EAAT2 protein in COS7 cells. COS7 cells expressing GFP, wild-type EAAT2-GFP, partial intron
7±retention EAAT2-GFP, or exon 9±skipping EAAT2-GFP proteins were examined by fluorescent microscopy. Aberrant proteins (exon-9
skipping-GFP, partial intron 7±retention-GFP expressed alone or with wild-type EAAT2) were largely confined to the cytoplasm, compared to
normal surface membrane localization of EAAT2. A coexpression of the GFP-labeled EAAT2 with the unlabeled partial-intron 7±retention
EAAT2 revealed that the aberrant protein interfered with the localization of wild-type protein in the surface membrane. Magnification, 4003.
All transfection experiments were repeated five times in triplicate. 3H-glutamate transport is expressed as mean transport 6 SEM compared
to control.
EAAT2-GFP with wild-type EAAT2 (not GFP-labeled) protein was localized on the cell surface when ex-
pressed alone or with the exon-9 skipping EAAT2 (Figure(Figure 7B). These results suggest that the partial intron
7±retention EAAT2 protein may interfere with normal 7B), and (3) the partial intron 7±retention EAAT2 (not
GFP-labeled) still interfered with the wild-type EAAT2EAAT2 protein complex assembly or trafficking. These
results were not seen with the exon-9 skipping EAAT2, protein trafficking to the cell membrane.
Eight other aberrant cDNAs were also expressed (de-which did not interfere with wild-type EAAT2 localization
(Figure 7B). Importantly, the abnormal protein localiza- scribed in Figure 1B) in COS7 cells. Two of them, shown
at Figures 1B4 and 1B7, also showed a dominant down-tion is probably not due to the influence of the GFP
fusion because (1) wild-type EAAT2-GFP±transfected regulation effect on normal EAAT2 activity and protein
expression like the partial intron 7±retention EAAT2cells had normal glutamate uptake, (2) the wild-type GFP
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cDNA, whereas the remaining cDNAs were unstable and with retinoic acid receptors, ultimately dominantly down-
regulating vitamin D signaling (Ebihara et al., 1996).inactive like the exon 9±skipping EAAT2 cDNA.
Can Aberrant EAAT2 mRNA Contribute
to Motor Neuron Degeneration?Discussion
Interestingly, the aberrant EAAT2 mRNAs were re-
stricted to motor cortex and spinal cord, the primaryLoss of EAAT2 Protein in ALS Is Due
to Aberrant EAAT2 Transcripts regions of neurodegeneration. Because ALS is charac-
terized by the death of motor neurons, it is possible thatFunctional glutamate transport is deficient in ALS, and a
substantial proportion of patients with sporadic disease these aberrant EAAT2 transcripts are secondary to a
motor neuron degeneration, or an astrocyte responsehave a large loss of the EAAT2 glutamate transporter
protein. In this study, our results provide evidence that to neuronal degeneration, or both. We did not find a
loss of EAAT2 or the presence of aberrant EAAT2 mRNAthe loss of EAAT2 protein in ALS may be due to aberrant
EAAT2 mRNA, possibly as a consequence of abnormal species in a subset of ALS patients, all of whom had
pathological confirmation of motor neuron loss. NeitherRNA splicing. The evidence for this conclusion includes
the following. (1) The aberrant EAAT2 transcripts were were they found in other neurodegenerative diseases,
such as SMA, Alzheimer's, or Huntington's diseases,found only in ALS motor cortex and spinal cordÐthe
only regions where there was a concomitant loss of which are also characterized by slow loss of neurons
(including motor neurons) and astrogliosis. Similarly, theEAAT2 protein (Figure 2). (2) In situ hybridization studies
indicated that loss of EAAT2 protein (Rothstein et al., partial intron 7±retention and the exon-9 skipping EAAT2
mRNA were not found in transgenic mice carrying a1995) in ALS motor cortex appeared to be associated
with the presence of the aberrant EAAT2 transcripts in familial ALS SOD1 mutation (G37R) (unpublished data).
The aberrant mRNA species were also detected in pa-vivo (Figure 3). (3) S1 nuclease protection assay and
quantitative RT-PCR revealed that, in ALS specimens tient CSF up to 4 years prior to death. Thus, the aberrant
mRNA species are not likely to be simply a result ofwith low EAAT2 protein, the majority of EAAT2 mRNA
was in the form of aberrant splicing products (Figure 4). motor neuron loss or postmortem artifact.
Antisense knockdown studies demonstrate that loss(4) Screening studies revealed that the aberrant EAAT2
mRNA is commonly present in sporadic ALS patients. of EAAT2 can lead to excitotoxic neuronal degenera-
tion and a progressive syndrome of motor impairmentAbout 65% of all postmortem specimens have one or
both of the partial intron 7±retention and exon 9±skip- (Rothstein et al., 1996). EAAT2 null mice also develop
excitotoxic neuronal degeneration (Tanaka et al., 1997).ping transcripts. The relative quantity of these abnormal
EAAT2 mRNAs correlated with the degree of EAAT2 Thus, even if aberrant EAAT2 transcripts are due to an
astrocyte response to neuronal degeneration or otherprotein loss in ALS tissue (Figure 5). (5) Studies of CSF
from living patients also independently confirmed their factors, the subsequent lossof EAAT2 could act toprop-
agate motor neuron degeneration in ALS. The clinicalspecific association with ALS (Figure 2B). (6) And finally,
in vitro expression studies suggested that proteins efficacy of anti-glutamate drugs in ALS and transgenic
models of ALS (Bensimon et al., 1994; Gurney et al.,translated from these aberrant EAAT2 mRNAs may un-
dergo rapid degradation and produce, in vitro, a domi- 1996; Lacomblez et al., 1996) support the notion that
glutamate-mediated toxicity, in part due to the loss ofnant negative effect on normal EAAT2 resulting in loss
of protein and activity (Figures 6 and 7). Taken together, EAAT2, could contribute to the pathogenesis of ALS.
these studies suggest that the presence of the aberrant
EAAT2 mRNA may directly relate to the loss of EAAT2 What Is the Origin of the Aberrant
protein commonly found in sporadic ALS. EAAT2 Transcripts?
The origin of the abnormal mRNA has not been deter-
mined, but one can speculate on several possible mech-How Does Mutant Protein Dominantly
Downregulate Normal EAAT2 Protein? anisms. It could result from relaxation of RNA processing
fidelity or an abnormality in the pathway for degradationThe mechanism by which the mutant proteins interfere
with wild-type EAAT2 activity is not known. Little is of mutant mRNA. In C. elegans, smg genes appear to
participate in the degradation of some, but not all, mu-known about glutamate transporter membrane organi-
zation or trafficking. Limited data suggests that under tant mRNAs (Morrison et al., 1997). The presence of
multiple aberrant EAAT2 mRNAs strongly suggests po-normal conditions, EAAT2 monomers may self-associ-
ate to form homomeric multimers in vivo (Haugeto et tential defects in RNA processing. Oxidative stress
could damage DNA encoding RNA processing proteinsal., 1996). It may be that the heteromers composed of
mutant truncated EAAT2 and wild-type EAAT2 protein or could damage the proteins responsible for RNA pro-
cessing. Damaged RNA processing proteins could leadsubunits undergo rapid degradation, as suggested by
our studies. This could explain the loss of EAAT2 in to relaxation of RNA processing fidelity, which may con-
tribute toabnormal gene expression. Interestingly, SMN,COS7 cell expression experiments and in ALS, although
other processes may be responsible. Examples of such the gene responsible for spinal muscular atrophy, an-
other motor neuron disease, has been found to codedominant-negative interactions between multimeric pro-
teins is not uncommon. For example, a retained intron for a protein that is a newly described component of
the RNA processing complex (Fischer et al., 1997; Liufor the vitamin D receptor leads to a truncated protein
in mice. This protein subsequently forms heterodimers et al., 1997). SMN protein appears to part of a protein
Aberrant Glutamate Transporter mRNA in ALS
599
complex responsible for the assembly of common small be due to aberrant EAAT2 transcripts. Disorders of RNA
processing, either as a primary defect as in spinal mus-nuclear ribonucleoproteins, and as such may participate
in the actions of RNA processing. Loss of SMN in spinal cular atrophy or secondary to other cellular defects,
could be important mechanisms for neurodegenerativemuscular atrophy can be lethal and causes motor neu-
ron degeneration, perhaps because of interference with disease. Ultimately, identification of the events that lead
to aberrant RNA processing could provide an opportu-RNA processing. There may be acquired damage to
RNA processing proteins, such as SMN protein, which nity for the development of specific therapies designed
to prevent the loss of glutamate transport in ALS. Thesubsequently leads to aberrant splicing of EAAT2 in
affected ALS brain regions. Because abnormal pre-RNA observation that these aberrant EAAT2 mRNA species
are commonly present in sporadic ALS and can be de-processing may be a cause of spinal muscular atrophy,
a future evaluation of EAAT2 RNA in SMA would be tected in the CSF of ALS patients may also provide an
important tool for development of a sensitive test forinteresting.
If these aberrant mRNA species are due to a region- early diagnosis of the fatal disease, allowing for early
initiation of treatments designed to prolong survival.or cell-specific defect in RNA processing, then other
aberrantly processed RNA species may be discovered
in future studies. EAAT1 is the other astroglial glutamate Experimental Procedures
transporter and has a genomic structure similar to
Tissue and CSF SpecimensEAAT2 (Hagiwara et al., 1996; Stoffel et al., 1996; Meyer
ALS brain and spinal cord tissue was obtained from the Johnset al., 1997; Aoki et al., 1998). Protein levels for EAAT1
Hopkins ALS Brain Bank and the Alzheimer's Disease Researchare normal in ALS (Rothstein et al., 1995), and aberrant
Center Brain Bank, with institution-approved informed consent.
mRNA species were not seen in the current study. Postmortem delays for autopsy were generally less than 12 hr. ALS
Alternatively, aberrant EAAT2 could be the result of and some control tissue was rapidly dissected by either one of us
(J.D.R) or by Neuropathology faculty at Johns Hopkins. Dissectedsomatic mutations of the EAAT2 gene. Mutations at the
regions were rapidly frozen using isopentane/dry ice, and thenintron±exon boundaries are often the cause of aber-
stored at 2758C until use. Additional specimens were fixed in 4%rant RNA splicing. Mutations within intronic regions, al-
paraformaldehyde. Pathological confirmation of ALS was made on
though less common, can also produce altered RNA all specimens by standard histological evaluation of spinal cord and
processing. Single mutations in intronic or exonic DNA motor cortex, with use of hematoxylin and eosin to evaluate motor
have been found to result in exon-skipping and intron- neuron loss, and with myelin stains (Luxol-fast blue) to establish
corticospinal tract degeneration. SOD1 mutation analysis was per-retention (Kuivenhoven et al., 1996; Sakai et al., 1996;
formed by R. H. Brown, Harvard University. Pathologically confirmedWang et al., 1996). In some disorders, such as choles-
Alzheimer's disease and Huntington's disease brain tissue was pro-teryl ester transfer protein deficiency (Sakai et al., 1996),
vided by the Johns Hopkins Alzheimer's Disease Research Centerintronic mutations can be distant from the intronic reten-
Brain Bank. SMA spinal tissuewas obtained atautopsy from patients
tion, or theexon-skipping regionsof theprocessed RNA, diagnosed by one of us (T.C.). CSF was obtained at the time of
or both. However, a recent extensive study of EAAT2 diagnostic evaluation for ALS and control patients with institution-
approved informed consent. CSF was rapidly frozen and stored atexon±intron splice sites in sporadic and familial ALS did
2208C to 2708C for up to 6 years.not reveal the presence of mutations, ruling out intra-
The clinical diagnosis of ALS was made by the El Escorial criteriagenic DNA mutations of EAAT2 as a cause of the aber-
(Brooks, 1994), including the presence of both upper and lower
rant mRNA species in our study (Aoki et al., 1998). The motor neuron signs, a definite history of progression, absence of
fact that aberrant EAAT2 transcripts were found in neu- sensory abnormalities, normal nerve conduction velocities and late
ropathologically affected areas in ALS suggests that responses, and electromyographic evidence of diffuse denervation.
Patients typically were initially classified as having either probablethere could be somatic alterations of the EAAT2 gene
or definite ALS based on these criteria. Patients were excludedrestricted to motor cortex and spinal cord. Previous
if they had unexplained bowel or bladder changes or anatomic,studies have documented evidence for both oxidative
metabolic, or toxic disorders that could mimic ALS, e.g., endocrineprotein damage and DNA damage in sporadic ALS
abnormalities, hexosaminidase A deficiency, lead intoxication, my-
(Bowling et al., 1993; Borthwick et al., 1996; Beal et al., elopathy, or peripheral neuropathy.
1997; Ferrante et al., 1997a, 1997b). Oxidative stress
could damage DNA encoding EAAT2 or could damage Immunoblot
the proteins responsible for DNA repair and eventually Immunoblots were performed as described previously (Rothstein et
al., 1995) on 4±25 mg of crude homogenate from motor cortex orlead to somatic alterations of EAAT2. Significantly, loss
from homogenized transfected COS7 cells grown on 75 mm plasticof EAAT2 can cause excitotoxic neuronal (including mo-
culture plates (CoStar), with affinity-purified polyclonal antibodiestor neuron) degeneration (Rothstein et al., 1996), and
to the carboxyl-terminal region of EAAT2 (Rothstein et al., 1995) or
excitotoxicity can induce generation of free radicals and to green fluorescent protein (GFP) (1:2000; Clontech). Glutamate
DNA damage (Campagne et al., 1995; Didier et al., 1996). transport was measured as described (Rothstein et al., 1992) except
Accumulating evidence suggests that ALS, the proto- using intact COS7 cells grown on 30 mm, six-well plates (CoStar).
typical motor neuron disease, may have multiple differ-
ent pathogeneses. Furthermore, primary defects (e.g., EAAT2 Cloning
Poly (A) mRNA was isolated using the FastTrack 2.0 mRNA isolationSOD1 mutations) may initiate a cascade of secondary,
kit (Invitrogen). cDNA was synthesized from the isolated mRNA bybut potent, toxic events in the nervous system that are
using ZAP express cDNA synthesis kit (Stratagene). The cDNA wasultimately responsible for motor neuron degeneration.
size fractionated into three fractions, .6 kb, 3±6 kb, and ,3 kb, by
Loss of EAAT2 protein is a potent toxic event because Sephacryl S-500 spin column. Each cDNA fraction was ligated into
it can lead toexcitotoxic neuron degeneration (Rothstein the ZAP express vector arms and packaged into Gigapack III Gold
et al., 1996; Tanaka et al., 1997). Our study provides packing extract (Stratagene). The cDNA library was subsequently
screened by a DNA probe prepared from full length EAAT2 cDNAevidence that the loss of EAAT2 protein in ALS could
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by random priming. The positive clones in the pBK-CMV phagemid C (59-ACGCTGGGGAGTTTATTCAAGAAT-39) corresponding to posi-
tion 1768 from the 59 translation region; Primer D (59-ACCGTCCTCTwere obtained after in vivo excision from the ZAP express vector
with ExAssist helper phage. GCCACCACTCT-39) corresponding to position 2428. Primers used
for RT-PCR of EAAT1 were as follows: 59-AGGAGGTTTGGCTTTCTG
TGG-39 corresponding to position 273; 59-GGTTTTTAACACCTGGTRT-PCR
GCTCAA-39 corresponding to position 1655 from the 59 translationPoly(A) mRNA was isolated from 50-100 mg of specimens (motor
region. Primers used for RT-RCR of SMN were as follows: 59-cortex, frontal cortex, hippocampus, caudate, cerebellum, and lum-
GCGGGTTTGCTATGGCGATGA-39 corresponding to position 211;bar orcervical spinalcord) by using Micro-Fast TrackKit (Invitrogen).
59-CAGCCATGTCCACCAGTTAGA-39 corresponding to position 1398The isolated mRNA was treated with DNase I for 20 min, heated to
from the 59 trasnslation region. Oligonucleotides used for preparing658C for 5 min, and then reverse transcribed into cDNA. A 25 ml
probes were as follows: 59-CGGCTGACTTTCCATTGGCTG-39 corre-reverse-transcription reaction mixture containing 50 ng of mRNA, 1
sponding to position 1664 from the 59 translation region of EAAT2;mM dithiothreitol, 0.5 mM dNTPs, 20 units of RNasin, 200 units of
59-CCTGGTGCTCAAGAAAGTGTTTC-39 corresponding to positionM-MLV reverse transcriptase (BRL), 13 buffer, and 0.5 mM primer
1664 from the 59 translation region of EAAT1; 59-TTTTGCCACATAC(primer B for the intron-retention and primer C for the exon 9±skip-
GCCTCACA-39 corresponding to position 1369 from the 59transla-ping and the full-length cDNA) was incubated at 428C for 60 min,
tion region of SMN.heated to 658C for 5 min, and quick-chilled on ice. PCR was per-
formed at a final concentration of 13 PCR buffer/0.2 mM dNTPs/
0.5 mM each 59 and 39 primers (primers A and B for the intron- In Situ Hybridization
retention; primers A and C for the exon 9±skipping; primers D and In situ hybridization was performed with digoxigenin-UTP±labeled
C for the full length; Figure 1)/2 U of Taq polymerase (Boehringer RNA probes generated from 1 mg of DNA template using the Maxi-
Mannheim)/2.5 ml of reverse transcription reaction mixture in a total script in vitrotranscription kit (Ambion, CA). The probes for detecting
volume of 50 ml. The mixture was overlaid with mineral oil and then wild-type EAAT2 mRNA and the partial intron 7±retention mRNA are
amplified with the Delta Cycler II thermal cycler (Ericomp) for 25 or indicated in Figure 1 as probes E and F, respectively. Specificity
30 cycles. The amplification profile involved denaturation at 948C controls included sense RNA probes and pretreatment of tissue
for 30 s, primer annealing at 558C for 30 s, and extension at 728C with RNase A (10 mg/ml) in 23 SSC at 378C for 30 min. An actin
for 1 min. PCR products (10 ml) were resolved by 1.2% agarose gel control provided with the kit contained z250 bp of b-actin fragment
electrophoresis and transferred to membrane. The blot was probed in the antisense orientation. Frozen tissue was sectioned (8 mm),
with a 32P-labeled EAAT2 cDNA probe prepared by the random fixed with 4% paraformaldehyde in 0.1M phosphate buffered saline
priming method (Figures 2A and 6) or a 32P-end labeled oligonucleo- (PBS; pH 7.4), rinsed with PBS, treated with 0.2% Triton X-100,
tide probe (Figures 2B, 2C, 4A, and 4C) and then subjected to autora- rinsed again with PBS followed by proteinase K1 (1 mg/ml) in TE
diography. The same RT-PCR conditions were used to analyze buffer (100 mM Tris-HCl, 50 mM EDTA [pH 8.0]) at 378C for 30
EAAT1 mRNA. min, then rinsed with 0.1 M glycine in PBS, and again with 4%
To screen for intron-retention mRNA, a plasmid (pE2F) was con- paraformaldehyde in PBS. The sections were acetylated with 0.25%
structed for use as an internal control for the comparative analysis acetic anhydride in TE with 0.1 triethanolamine, rinsed with DEPC
of the intron-retention mRNA between patients. A 185 bp DNA frag- water, air dried, and then hybridized overnight with probe (2 ng/ml)
ment with HindIII on both ends was inserted into the intronic mutant in hybridization buffer (50% deionized formamide, 53 SSC, 10%
cDNA at a HindIII site (indicated in Figure 1, triangle). This plasmid, dextran sulfate, 53 Denhardt solution, 2% SDS, 100 mg/ml dena-
pE2F, was used as a template for transcription by the T3 polymerase. tured salmon sperm DNA). The single-stranded RNA probe was
The resulting pE2F complementary RNA (cRNA) product was puri- removed with RNase A (10 mg/ml) at378C for 30 min. The immunolog-
fied by oligo(dT) chromatography. Fifty nanograms of mRNA isolated ical detection of the digoxigenin-labeled RNA probe was performed
from human tissue and 5 pg of cRNA were combined and then using alkaline phosphatase-conjugated anti-digoxigenin antibody
reverse transcribed into cDNA by using primer B (Figure 1). The (Boehringer Mannheim) at 1:200 and standard reagents for alkaline
cDNA mixture was then amplified for 25 cycles. Under these condi- phosphatase.
tions, the reaction rates of pE2F cRNA and intron-retention mRNA
were identical within an exponential phase of the PCR reaction.
In Vitro Expression and ConstructionBecause the exon-skipping mRNA was 135 bp shorter than the wild-
of EAAT2-GFP Fusion Genetype EAAT2 mRNA, the wild-type EAAT2 mRNA was used as an
Wild-type as well as aberrant cDNA fragments were cloned into ainternal control for the comparative analysis of the exon-skipping
eukaryotic expression vector (pcDNA3). The constructed plasmidsmRNA between patients. Using the internal controls as standards,
were then transfected into COS7 cells or HeLa cells by electropora-the relative amounts of intron-retention and exon 9±skipping mRNA
tion. Electroporation (Bio Rad ªGene Pulser IIº, 300 V at 500 mF)were calculated and compared, between patient samples, by densi-
was performed on 1 3 107 cells in a solution of DMEM containingtometric analysis of Southern blots.
500 mg of salmon sperm DNA along with the pcDNA3 plasmid con-For CSF studies, 400 ml CSF was centrifuged (1500 3 g) for 10
taining the transporter subtype.min to pellet blood cell debris. Total RNA was isolated from the
For construction of the EAAT2-GFP fusion gene, wild-type orsupernatant using QIAamp kit (Qiagen). Poly(A) mRNA was further
aberrant EAAT2 cDNA in pcDNA3 was amplified by PCR using (1)isolated and subjected to RT-PCR procedures as described above.
strand T7 primer and (2) strand primer (for wild-type and exon-EAAT2 is only expressed by CNS tissue. No wild-type or exon
skipping mutant using 59-GGATCCCGGGCCCTTTCTCACGTTTCCA9±skipping EAAT2 mRNA was detected from the pelleted blood cell
AGG-39; for partial intron 7±retention species using 59-GGATCCCGdebris.
GGCCCCCTGGAAGCGGTGCCCAG-39). To create a restriction site
for cloning purposes, we added a 13 sequence (shown underlined)Cloning of PCR Products and Sequencing
at the 59 ends of the primer to create ApaI. The resultant PCRPCR products were isolated from agarose gel by using QIAquick
products were digested with EcoRI and ApaI and then cloned intoGel Extraction Kit (Qiagen). They were then cloned into a pCR 2.1
the N terminus of the GFP gene in pEGFP-N2 vector (Novagen).vector (TA Cloning Kit, Invitrogen). Plasmid DNA was isolated from
Sequences of the chimeric genes were checked at their fusion sites.transformed cells by using PERFECT prep Plasmid DNA kit (5 prime
→ 3 prime, Inc.). Sequencing of the DNA was carried out on an
Automated DNA Sequencer (Applied Biosystem). S1 Nuclease Protection Assay
A 836 base single strand DNA probe was generated by asymmetry
PCR using primers A and C. PCR conditions are the same as de-Oligonucleotides
Primers used for RT-PCR of EAAT2 were as follows: Primer A (59- scribed above, except 0.05 mM primer A and 0.5 mM primer C were
used. The expected single strand DNA was isolated from the gel.GGCAACTGGGGATGTACA-39) corresponding to position 933 from
59 translation region; Primer B (59-CCAGAAGGCTCAAGAAGT-39) For hybridization and S1 nuclease analysis, 0.5 pmol of single strand
DNA probe was mixed with 1 mg of the mRNA sample and hybridizedcorresponding to position 170 from exon 7-intron junction; Primer
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in a solution containing 80% formamide, 0.4 M NaCl, 40 mM pipera- Bruijn, L.I., and Cleveland, D.W. (1996). Mechanisms of selective
motor neuron death in ALS: insights from transgenic mouse modelszine-N,N9-bis (2-ethanesulfonic acid) (PIPES; pH 6.4), and 1 mM
EDTA for 16 hr at 558C. Samples were then diluted 15-fold with ice- of motorneuron disease. Neuropathol. Appl. Neurobiol. 22, 373±387.
cold S1 nuclease buffer (BRL) and treated with 0.5 U of S1 nuclease Campagne, M.V., Lucassen, P.J., Vermeulen, J.P., and Balazs, R.
per microliter at 258C for 1 hr. The protected fragments were re- (1995). NMDA and kainate induce internucleosomal DNA cleavage
solved by 1.5% agarose gel electrophoresis and transferred to mem- associated with both apoptotic and necrotic cell death in the neona-
brane. The blot was probed with an oligonucleotide probe located tal rat brain. Eur. J. Neurosci. 7, 1627±1640.
at the 39 end of the protection fragment (described above) and then Carriedo, S.G., Yin, H.-Z., Lamberta, R., and Weiss, J.H. (1995).
subjected to autoradiography. In vitro kainate injury to large, SMI-32(1) spinal neurons is Ca21
dependent. Neuroreport 6, 945-948.
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